PamDx, a 's-Hertogenbosch, Netherlands-based contract research organization specializing in functional kinase activity profiling, has raised €13 million ($15.3 million) in Series A funding led by Myosotis Investments. The company offers kinase screening services via its proprietary PamChip peptide microarray technology and develops the CE-IVD registered IOpener blood test to predict immunotherapy responses in melanoma and NSCLC patients from peripheral blood mononuclear cells. The proceeds will support clinical utility studies and commercialization of IOpener.
Liquid Biopsy Funding Heats Up
PamDx's raise follows a wave of early 2026 investments in liquid biopsy technologies. Cyclomics raised €2.6 million in January to advance oncology diagnostics, while BIOCAPTIVA secured £1.58 million in March for cfDNA sample prep kits. This activity signals strong investor interest in tools improving precision oncology, where PamDx differentiates with functional kinome data from minimal blood samples over genomic-focused approaches.
Kinase Assays Fill Biomarker Gaps
Current immuno-oncology biomarkers like PD-L1 struggle to predict checkpoint inhibitor responses reliably. Functional kinase profiling addresses this by measuring active signaling pathways directly from patient samples, revealing therapy resistance mechanisms invisible to genomics or proteomics. PamDx's platform complements these modalities, targeting the rising demand for companion diagnostics in kinase-targeted therapies.
PamChip Enables Functional Kinomics
PamDx's core technology, the PamChip array, performs multiplex assays on clinical lysates or PBMCs to profile kinase-substrate interactions in native contexts. Unlike recombinant enzyme screens from competitors like Reaction Biology or BPS Bioscience, it captures disease-specific activity for biomarker discovery and patient stratification. The IOpener test, now CE-IVD marked, processes a single blood tube to guide treatment in metastatic cancers.
As John Groten, Managing Director, noted:
“Securing this Series A funding is a powerful validation of our team’s hard work and the disruptive potential of our IOpener® technology.”
Strategic Investors Back Commercial Pivot
Myosotis Investments, a 2024-founded firm focused on molecular diagnostics, led the round with participation from the European Innovation Council (EIC) Fund and existing shareholders. This builds on PamDx's €7.5 million EIC Accelerator grant in 2023. The investor mix reflects conviction in transitioning PamDx from CRO services to diagnostic commercialization amid EU precision medicine priorities.
Wietse Mulder, Managing Partner at Myosotis, highlighted the shift:
“We are pleased to support PamDx as they transition from a breakthrough innovator to a commercial-stage player in the diagnostics space.”
Liquid Biopsy Market Scales Rapidly
The liquid biopsy market stands at $7.05 billion in 2025, projected to reach $22.69 billion by 2034 at 13.91% CAGR. Oncology companion diagnostics follow suit, growing from $5.09 billion in 2024 to $8.38 billion by 2030. Kinase biology services underpin this at $23.38 billion with 6.8% CAGR.
Long-Tenured Team Drives Continuity
Leadership boasts 30+ years in life sciences, with roots in PamDx's 2001 origins as a PamGene spin-out from Organon Teknika. Managing Director John Groten held C-level roles at Harlan Laboratories and Merck Sharp & Dohme. Recent addition Gitanjali Dharmadhikari brings oncology R&D from Philips and a single-cell spin-out success, strengthening biomarker programs.
Clinical Trials and Hiring Ahead
PamDx plans clinical utility studies for IOpener in melanoma and NSCLC, alongside scaling sales and partnerships. Recent hiring includes an Account Manager in 's-Hertogenbosch, signaling commercial expansion. Conference presence at AACR 2026 with seven posters underscores ongoing validation through customer publications and kinomics initiatives.